A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KITE)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Brolucizumab (Primary) ; Aflibercept
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms KITE
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2018 Status changed from not yet recruiting to recruiting.
- 18 Jun 2018 Planned initiation date changed from 1 Jul 2018 to 2 Aug 2018.